Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), a United States-based biotechnology company, announced on Thursday that it has named Kyle Jenne as its new executive vice president, chief global product strategy officer.

Jenne is to head all aspects of commercialisation at the company.

Jenne has over 25 years of biopharmaceutical commercial and executive leadership experience and has introduced innovative medicines across a wide range of therapeutic areas that include cardiovascular, neurology and allergy. He has served for five years in commercial leadership roles at Ionis and Akcea. Most recently, he served as EVP & chief commercial officer at Ionis. He has served in commercial roles for companies including Schering Plough, King Pharmaceuticals, Acorda Therapeutics and Praecis Pharmaceuticals.